Stock market analyst Ashwani Gujral has maintained ‘Buy’ rating on Dr Reddy`s Laboratories to achieve a target between Rs 765- Rs 800 in 1-2 trading sessions.

According to Mr. Gujral, interested traders can buy the stock with a strict stop loss of Rs 718.

The shares of the company, on Tuesday (June 20), closed at Rs 743.65 on the Bombay Stock Exchange (BSE). Current EPS and P/E of the stock stood at 33.29 & 22.54 respectively. The share price has seen a 52-week high of Rs 764 and a low of Rs 357 on BSE.

Dr Reddy`s Laboratories, on June 23, has introduced Bispec™ (Solifencin Succinate) in the Indian market. Bispec™ is prescribed for the management of over active bladder (OAB).

It is available in the form of a tablet in dosages of 5 mg and 10 mg. It is the best available drug for OAB and rarely results in the occurrence of dry mouth and constipation.

Dr Reddy`s Laboratories (DRL), on June 16, announced that it is planning to hire around 1,300 people during the existing fiscal, comprising about 350 via campus recruitment.

DRL also said that around 300 people had already joined and the remaining would join in different stages.

In all, the company has around11,000 employees, out of which 12% are women and 20% work abroad. The attrition rate has declined to 12% from 18%.

On June 15, Dr Reddy`s Laboratories declared that it has signed up a partnership deal with GlaxoSmithKline (GSK) in order to make and sell select products across growing aboard markets.

Under the deal, which is effective immediately, GSK will gain access to Dr Reddy`s rich and diverse collection and future pipeline of over 100 branded pharmaceuticals in aggressive therapeutic sectors including cardiovascular, diabetes, oncology, gastroenterology and pain management.